Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS –
4.3.1 MICRO AND MACROECONOMIC FACTORS
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.3.3 KEY PRICING STRATEGIES
4.3.4 ANALYSIS AND RECOMMENDATION
4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 MERGERS & ACQUISITIONS
4.4.1.2 TECHNOLOGY COLLABORATIONS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES & MILESTONES
4.4.5 INNOVATION STRATEGIES & METHODOLOGIES
4.4.6 RISK ASSESSMENT & MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PIPELINE ANALYSIS – NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.5.2 DRUG THERAPY PIPELINE
4.5.3 PHASE III CANDIDATES
4.5.4 PHASE II CANDIDATES
4.5.5 PHASE I CANDIDATES
4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH)
4.5.7 CONCLUSION
4.6 EPIDEMIOLOGY–
4.6.1 INCIDENCE OF LYMPHEDEMA (NORTH AMERICA & BY GENDER)
4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER
4.6.3 TREATMENT RATE
4.6.4 MORTALITY RATE
4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.6.6 PATIENT TREATMENT SUCCESS RATES
4.7 TARIFF
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 North America vs. Regional Tariff Structures
4.7.2.2 United States: Medicare/Medicaid Tariff Policies, CMS Pricing Models
4.7.2.3 European Union: Cross-border Tariff Regulations and Reimbursement Policies
4.7.2.4 Asia-Pacific: Government-imposed Tariffs on Imported Medical Products
4.7.2.5 Emerging Markets: Challenges in Tariff Implementation
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 Import Duties on Prescription Drugs vs. Generics
4.7.3.2 Impact on Drug Affordability and Access
4.7.3.3 Key Trade Agreements Affecting Pharmaceutical Tariffs
4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.7.4.1 Cost Burden on Hospitals and Healthcare Facilities
4.7.4.2 Effect on Patient Affordability and Insurance Coverage
4.7.4.3 Tariffs and Their Role in Medical Tourism
4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.7.5.1 WTO Regulations on Healthcare Tariffs
4.7.5.2 Impact of Trade Wars on the Healthcare Supply Chain
4.7.5.3 Role of Free Trade Agreements (FTAs) in Reducing Tariffs
4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
5 REGULATORY FRAMEWORK–
5.1 NORTH AMERICA
5.2 SOUTH AMERICA
5.3 EUROPE
5.4 ASIA-PACIFIC
5.5 MIDDLE EAST & AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY
6.1.2 INCREASE IN THE PREVALENCE OF CANCERS
6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS
6.2 RESTRAINTS
6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT
6.2.2 LACK OF AWARENESS ABOUT THE DISEASE
6.3 OPPORTUNITIES
6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS
6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS
6.4 CHALLENGES
6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT
6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES
7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 COMPRESSION THERAPY
7.3 SURGERY
7.4 DRUG THERAPY
7.5 LASER THERAPY
7.6 OTHERS
8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 SECONDARY LYMPHEDEMA
8.3 PRIMARY LYMPHEDEMA
9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
9.1 OVERVIEW
9.2 LOWER EXTREMITY
9.3 UPPER EXTREMITY
9.4 GENITALIA
10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 GERIATRIC
10.4 PEDIATRIC
11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 INJECTABLE
11.4 TOPICAL
12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 PHARMACY STORES
13.3 DIRECT TENDER
13.4 OTHERS
14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TACTILE MEDICAL
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 ESSITY AKTIEBOLAG (PUBL)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 3M
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 CARDINAL HEALTH
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 LOHMANN & RAUSCHER GMBH & CO. KG
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 AIROS MEDICAL, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ARJO
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 AVET PHARMACEUTICALS INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BAUERFEIND
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BIOCOMPRESSION SYSTEMS
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 CONVATEC INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 ENOVIS CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 HUNTLEIGH HEALTHCARE LIMITED
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 IMPEDIMED LIMITED
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT/NEWS
17.15 JODAS EXPOIM PVT. LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 JUZO
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 KOYA MEDICAL
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 LLC BINNOPHARM GROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 MCKESSON MEDICAL-SURGICAL INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 MEDI GMBH & CO. KG
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 MEDTRONIC
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MEGO AFEK LTD
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 PAUL HARTMANN AG
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 PERFORMANCE HEALTH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PURETECH HEALTH INC
17.25.1 COMPANY SNAPSHOT
17.25.2 PIPELINE PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 SANYLEG SRL A SOCIO UNICO
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 SIGVARIS GROUP
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SMITH+NEPHEW
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENT
17.29 THERMOTEK
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 THUASNE
17.30.1 COMPANY SNAPSHOT
17.30.2 PRODUCT PORTFOLIO
17.30.3 RECENT DEVELOPMENT
17.31 VIATRIS INC.
17.31.1 COMPANY SNAPSHOT
17.31.2 REVENUE ANALYSIS
17.31.3 PRODUCT PORTFOLIO
17.31.4 RECENT DEVELOPMENT
17.32 WHITE SWAN PHARMACEUTICAL
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 PRODUCTS AND THEIR STAGES IN DEVELOPMENT.
TABLE 2 PHASE-WISE DISTRIBUTION: CLINICAL TRIALS
TABLE 3 PHASE 2 CANDIDATES
TABLE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 6 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2018-2032 (USD THOUSAND)
TABLE 7 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 8 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 45 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 59 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 60 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 61 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 62 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 63 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 68 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 69 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 70 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 74 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 75 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 76 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 77 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 78 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 83 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 84 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 85 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 86 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 87 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 89 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 90 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 91 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 92 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 93 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 98 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 99 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 FIVE SEGMENTS COMPRISE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE (2024)
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 14 INCREASE IN THE PREVALENCE OF CANCERS IS EXPECTED TO DRIVE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2025 AND 2032
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDONESIA ZEOLITE MARKET
FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2024
FIGURE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2024
FIGURE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2025-2032 (USD THOUSAND)
FIGURE 27 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2025-2032)
FIGURE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 29 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 31 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 33 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 34 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 36 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2024
FIGURE 38 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 46 North America Lymphedema Treatment Market: COMPANY SHARE 2024 (%)
